Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines.
about
Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxinClostridium perfringens epsilon toxin: a malevolent molecule for animals and man?Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agentsRabies virus glycoprotein as a carrier for anthrax protective antigenAnthrax vaccination strategiesA viral nanoparticle with dual function as an anthrax antitoxin and vaccineFunctions of phenylalanine residues within the beta-barrel stem of the anthrax toxin pore.Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodiesA chimeric protein that functions as both an anthrax dual-target antitoxin and a trivalent vaccine.A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 proteinCytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4.Structural and biological characterization of a capsular polysaccharide produced by Staphylococcus haemolyticus.Dermatan sulfate interacts with dead cells and regulates CD5(+) B-cell fate: implications for a key role in autoimmunityBiophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine.Designing inhibitors of anthrax toxinGlassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvantsConjugate-like immunogens produced as protein capsular matrix vaccines.Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax InfectionImmunization of Mice with Anthrax Protective Antigen Limits Cardiotoxicity but Not Hepatotoxicity Following Lethal Toxin ChallengeFrom structure to solutions: the role of basic research in developing anthrax countermeasures: Microbiology Graduate Program Seminar: Anthrax toxin.The Poly-γ-d-Glutamic Acid Capsule Surrogate of the Bacillus anthracis Capsule Is a Novel Toll-Like Receptor 2 Agonist.Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvantPhenylalanine-427 of anthrax protective antigen functions in both pore formation and protein translocation.Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism.Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination.Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.Dominant-negative inhibitors of the Clostridium perfringens epsilon-toxin.Anthrax vaccines: present status and future prospects.Glycan surface antigens from Bacillus anthracis as vaccine targets: current status and future perspectives.
P2860
Q24796044-6E73FF7C-FBE5-4C42-BD55-0B9579F910C8Q26859117-2D3B320C-5605-4E17-B402-671A3C91B209Q28384852-933E70CB-26E4-42BA-BDD8-64EACFE80BD7Q28391261-15381B8A-3D08-496B-A230-983363F854AFQ28392248-C244C968-1D04-49B2-8220-3723B4A05FA4Q28469319-A73CDC11-EE35-4CF6-A44D-975DA4B55D92Q30157196-CAA278EF-F385-4423-BF5D-C639A7D5D9CBQ34121874-25D5906A-0953-435D-A1C0-E87D4F7B3B75Q34289944-1A18B4C8-90E6-4223-8C63-DFB35B7CD9D6Q34328401-4EEB4505-C392-4D96-B1D7-6516D8FEAA48Q34334441-F1306DE7-6B2C-4AB8-A5AB-664D25F2029DQ34731479-0E6582A6-9754-4830-86D3-6477E51B9E96Q34839450-9CCCAAB0-9686-4E02-BB3C-2E8170C690DFQ34909572-BFCEFCB1-A91D-48F9-9CBC-912ACD422316Q35018313-CB2F2A42-4C8D-4E91-9C8F-293FAFBC1E08Q35032554-3C818071-47D5-4723-AFDA-24539D422DC0Q35189827-6AA991D5-625D-43C5-8E4F-0B30880C6A5AQ35710981-051866FC-54DB-437B-AFA2-5804DC8D893EQ35894690-F62E0DDA-D906-4F88-BE93-0D08F65A4053Q36033600-27F4F3FD-BD9C-45FF-B63C-02E3DE939A61Q36053487-2878FE88-2578-4536-A963-817F4B348E38Q36478354-C2F305E8-E22D-421D-A248-EA993E1AB4DAQ36593900-8BDD9C31-A626-404B-8D90-196D83DA9D22Q36670023-4A1B5DCD-F6BA-4255-8B83-4A517648D69AQ36901955-F46B8117-7DE5-448A-BE71-612B347B3A01Q37262118-B138A835-4721-43C6-B389-9E087105A8DBQ37355950-CBF119BA-0355-421E-9158-14D0A834F121Q37404847-D7411563-AC4A-4F49-9922-2FB2B0DD714EQ37447687-93D99B0B-7479-427D-986B-FA1AA3B41DDDQ38132268-629365F8-AB67-413E-A4A0-658B6FDABCA4Q38215454-8C900E6D-3106-4818-8CC9-EF25F0271E93
P2860
Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Combining anthrax vaccine and ...... d safe immunogen for vaccines.
@ast
Combining anthrax vaccine and ...... d safe immunogen for vaccines.
@en
type
label
Combining anthrax vaccine and ...... d safe immunogen for vaccines.
@ast
Combining anthrax vaccine and ...... d safe immunogen for vaccines.
@en
prefLabel
Combining anthrax vaccine and ...... d safe immunogen for vaccines.
@ast
Combining anthrax vaccine and ...... d safe immunogen for vaccines.
@en
P2093
P2860
P1476
Combining anthrax vaccine and ...... d safe immunogen for vaccines.
@en
P2093
Benedikt A Aulinger
John J Mekalanos
Julia Y Wang
Michael H Roehrl
P2860
P304
P356
10.1128/IAI.73.6.3408-3414.2005
P407
P577
2005-06-01T00:00:00Z